04 / Kintsu · HealthTech · SaaS · Controlled/Compliant environment

Turn demand into repeatable delivery.

Joined as Chief Product Officer in January 2024 and expanded to Product & Operations in February, with P&L responsibility. I partnered with the CEO on company vision, team formation and business priorities. Together, we connected clinical workflows, data and AI to build the product and operating capacity for repeatable B2B delivery.

~2.6×

revenue growth

combined business outcome

2 → 5

pharma relationships

reported contract progression

5,000+

patients reached

reported B2B2C reach

2×

physician engagement

reported engagement growth

Executive intervention

Create clarity before asking a remote company to move faster.

We relaunched the company and established BioPlanner as the scalable product platform. Shared priorities and context helped a fully remote team turn strategy into delivery.

Operating clarityProductizationDelivery capacityMore contractsRevenue growth

OKRs

Made priorities and ownership explicit.

Single source of truth

Made work, context and decisions persistent.

BioPlanner

Moved delivery toward a reusable Product core.

Productization & performance

Turn custom delivery into a scalable Product core.

Custom deliveryReusable Product coreConsistencyFaster implementationGreater capacity

Kintsu Product Flow Optimization analysis comparing the clinical journey before and after the redesign — View full analysis ↗

66.1%

lower interaction cost in the UX analysis

Interaction measure, not financial savings

38.5%

fewer pages

26 → 16

42.9%

shorter path to results

21 → 12 pages

47% → 72%

overall Product performance

measured journey score

Scale & business impact

A stronger delivery system increased the capacity to grow.

Product, Technology, Data and Operations redesigned the portfolio and operating model, reducing B2B time-to-market by approximately five months. The combined product, commercial and operating effort supported revenue growth, doubled physician engagement and three additional pharmaceutical contracts.

012 signed

starting relationships

02+3

new pharma relationships

035 total

reported contracted relationships

PharmaKintsu ProductPatient

External validation

The model earned outside attention.

R$3M

investment interest

Founder-reported interest; capital was not raised.

Janssen

acceleration ecosystem

Program participation supported external validation.

Eretz.bio

HealthTech ecosystem

Participation connected the company to the Einstein innovation ecosystem.

The breakthrough was not more custom work. It was making clinical value repeatable.